Overview of ACLS
Pharmacology
and
Update on New ACLS
Guidelines
Krista Piekos, Pharm.D.
Clinical Pharmacy Specialist - Critical Care
Harper University Hospital
Adjunct Assistant Professor
Wayne State University
Objectives
Pharmacists should be able to identify:
Why?
we use an agent
When?
to use an agent
How?
to use an agent
What?
...to watch for
To familiarize the pharmacist with the ACLS
algorithms
To help the pharmacist become comfortable
with the crash cart
To introduce the needless delivery system
Outline
Present conclusions of the International
Guidelines 2000 ACLS objectives with
2003 updates
Classification of recommendations
ACLS Algorithms
Pharmacology of agents used in
algorithms
Overview of crash cart revisions
Overview of needless system
Background
In Seattle 43% of patients in VF survived
to hospital discharge if CPR w/in 4 min
and defibrillation w/in 8 min
These figures are higher than national
average - due to AEDs throughout public
Overall survival from CPR is poor 5-15%
Survival for in-patient CPR to discharge
is <10%
Guidelines 2000 for
Cardiopulmonary
Resuscitation and
Emergency Cardiovascular
Care
1st international consensus on
resuscitation guidelines
Experts from around the world
Identified issues
Gathered scientific evidence; level (quality) of
evidence
Integrate into a class of recommendation
Revised guidelines
Classification of
Therapeutic Interventions
Class I: definitely helpful, excellent
Class II:
Class II a -probably helpful;
good to very good
Class II b -possibly helpful; fair to
good
Class Indeterminate: insufficient
evidence; no harm, but no benefit
Class III: possibly harmful
New Goals
1. Early Defibrillation - Public Access Defibrillation (PAD)
Probability of successful defibrillation and survival is negatively
related to the time from onset of VF to delivery of first shock
PAD has the potential to be the single greatest advance in the
treatment of prehospital sudden cardiac death since the invention
of CPR
Circulation August 22, 2000
2. Establishing a specific diagnosis by ECG
3. Antiarrhythmic agents are just as likely to be
proarrhythmic as they are antiarrhythmic.
One, and only one antiarrhythmic should be used.
Routes of
Administration
Intravenous
Preferred route
Endotracheal
2-2.5 Xs IV dose in 10ml volume
Each dose is followed by 10 ml NS flush down the ET tube
(Ex. epinephrine, atropine, lidocaine, diazepam, naloxone)
Absorption occurs at alveolar capillary interface
Intraosseous (active bone marrow)
Pediatric patients without IV access
Other: Sublingual, intracardiac, IM, SC (poor absorption)
ACLS
Algorithm
Approach
Universal Algorithm
Epinephrine
WHY?
Natural catecholamine with and -adrenergic agonist
activity
Results in:
flow to heart and brain
SVR, SBP, DBP
electrical activity in the myocardium & automaticity (
success with defibrillation)
myocardial contraction (for refractory circulatory shock
(CABG))
increases myocardial oxygen requirements
Primary benefit: -vasoconstriction
-adrenergic activity controversial b/c myocardial work
WHEN?
VF/VT, asystole, PEA, bradycardias
Epinephrine
HOW?
High dose versus standard dose?
Higher ROSC with high dose, but no change in survival
High doses may exacerbate postresuscitation myocardial dysfunction
Recommendations:
Class I: 1 mg IV q 3 - 5 min
Class IIb: 2-5mg IVP q3-5min, or 1mg-3mg-5mg
Class Indeterminate: high-dose 0.1mg/kg IVP q3-5min
Infusion for HR & BP (IIb)
1mg in 250ml NS or D5W - infuse @ 1-10 mcg/min
ET Dose=2-2.5 times IV dose
What to watch for?
Tachycardia, hypertension, myocardial ischemia, acidosis
Incompatible with Ca, HCO3, aminophylline & PHY. Alkaline solutions cause autooxidation.
Vasopressin
WHEN?
Alternative to epinephrine for shock-refractory VT/VF
WHY?
Natural antidiuretic hormone
Potent vasoconstrictor by stimulation of SM -V 1 receptors :
BP & SVR; CO, HR, myocardial O2 consumption and
contractility
Does not myocardial oxygen consumption
Not affected by severe acidosis
Class IIb for shock-refractory VF
Class Indeterminate for PEA, asystole
Half life = 10-20 minutes
Dose?
40 Units IVP - one time only!!!
Why Vasopressin?
During CPR, plasma ADH levels are higher in patients
with return of spontaneous circulation (ROSC)
During CPR patients may be severely acidotic
Epinephrine compared to vasopressin pre-hospital
CPR (20 patients/study group)
Multiple animal studies showing ROSC
EPI
Survival to hospital
24 hour survival
Discharge alive
(n=20)
VP
35%
(p=0.06)
20%
60%
15%
(p=0.16)
(n=20)
70%
(p=0.02)
40%
ILCOR Universal Algorithm
(International Liaison Committee on Resuscitation)
Medication changes in 2000:
Emphasis on identification of all possible
stroke victims for IV fibrinolytics
Epinephrine has become Class Indeterminate
High-dose epinephrine no longer
recommended
For shock-refractory VT/VF: Epinephrine 1 mg q 3-5
min
Vasopressin 40 Units IVP one time
Epinephrine alone for non-VT/VF
Pulseless Ventricular
Fibrillation
or Tachycardia
In ACLS, always assume VF - most common
85%-95% of survivors have VF
Survival dependant on early defibrillation
Medications indicated only after 3 failed shocks
VFib/Pulseless VT Algorithm
Please Shock-Shock-Shock, EVerybody Shock, And Let's Make Patients
Better
Please -
Precordial Thump If pulse-less with no defibrillator
Shock 200J*
Shock 200-300J*
Shock 360J*
(*only consecutive, if persistent)
EVerybody - Epinephrine 1 mg IV q3-5 min or Vasopressin 40 U IVP
If VF/PVT persists, "CONSIDER" antiarrhythmics and sodium bicarb. NOTE: always "max
out" one agent before proceeding to the next in order to limit pro-arrhythmic drug-drug
interactions
Shock 360J
And - Amiodarone (First Choice) 300mg IV push. May repeat once at
150mg in 3-5 min. (max. cumulative dose: 2.2g IV/24hrs)
Drug-shock-drug-shock sequence
(continued)
Please Shock-Shock-Shock, EVerybody Shock, And Let's Make Patients
Better
Let's - Lidocaine 1.0-1.5 mg/kg IV. May repeat in 3-5 min (max=3
mg/kg)
Make Magnesium Sulfate 1-2 g slow IVP for suspected Mg or
TdP
Patients- Procainamide 30 mg/min, or 100 mg IV q 5 min. for refractory
VF. (max. dose: 17 mg/kg)
NOTE: Besides having a pro-arrhythmic drug-drug interaction with amiodarone, procainamide is of
limited value in an arrest situation due to a lengthy administration time
Better (consider buffers) - Bicarbonate 1 mEq/kg IV for:
preexisting K+
bicarb-responsive acidosis
some drug overdoses
protracted code (intubated)
ROSC after long code with effective ventilation.
Drugs for VF/PVT
Epinephrine - Why? How? What?
Vasopressin - Why? How? What?
Amiodarone
Magnesium
Procainamide
Lidocaine
Buffers
Class
Drug
Ia
Quinidine
Procainamide
Disopyramide
Ib
Lidocaine
Mexiletine
Tocainide
Ic
Classification of
Antiarrhythmics
Conduction Velocity Refractory Period
Automaticity
Ion Block
Sodium
Sodium
(fast on-off)
0/
Flecainide
Propafenone
Moricizine
Sodium
(slow on-off)
II
Beta-Blockers
Calcium
III
Amiodarone
Bretylium
Sotalol
Potassium
IV
Verapamil
Diltiazem
0
Calcium
Drugs Used for Heart Rhythm
and Rate
Amiodarone
WHY?
Class III antiarrhythmic (characteristics of all classes)
Na, K and Ca channel blocker & & -adrenergic blocker
Prolongs AP and RP
Decreases AV conduction velocity & SN function
New Recommendations (WHEN?):
pulseless VT or VF (IIb)
hemodynamically stable VT (IIb), polymorphic VT (IIb),
wide-complex tachycardia uncertain origin (IIb)
refractory PSVT (preserved function, IIa; impaired function
IIb)
atrial tachycardia (IIb)
cardioversion of AF (IIa)
Amiodarone
HOW?
Cardiac arrest (PVT/VF) - 300mg IVP diluted
in 20-30ml, may repeat with 150mg in 10
minutes, or start infusion (max=2..2 g/24h)
Atrial & ventricular arrhythmias in impaired
hearts
150mg IVP over 10 min
May repeat q10-15 min, or start gtt 1mg/min x 6
hours, then 0.5mg/min x 18 h
WHAT?
Hypotension, bradycardia (slow rate, fluids)
Why Amiodarone?
ARREST Trial
Objective:
Efficacy of IV amiodarone in out-of-hospital
cardiac arrest due to ventricular fibrillation or
pulseless ventricular tachycardia
Endpoints:
Hospital admission with perfusing rhythm
Survival to discharge
Functional neurologic status at discharge
*Insufficiently powered to detect survival to discharge and
functional neurologic status*
ARREST Trial: Amiodarone in the
Resuscitation of Refractory
Sustained Ventricular
Tachyarrhythmias
Prospective, randomized, DB, PC trial
504 patients, who failed >/= 3 shocks
Randomized to placebo or 300mg IV amiodarone
Amiodarone Dosing:
300mg diluted with 5% D5W to 20mL
Rapid IV bolus
Found a statistically significant increase in the
number of patients who arrived to hospital alive
(p=0.03)
Consistent results regardless of presenting rhythm
This is the only antiarrhythmic agent which has shown definitive benefit in
cardiac arrest!
ARREST Trial - Subgroup
Analysis
% Surviving to
Admission
Amiodarone
70
60
50
40
30
20
10
0
Placebo
Drugs Used for Heart Rhythm
and Rate
Magnesium Sulfate
WHY? Magnesium deficiency causes arrhythmias
Facilitates ventricular repolarization by enhancing
intracellular potassium flux, dilates coronary
arteries
WHEN?
VT/VF,
Suspected hypomagnesemia, pulseless
torsade de pointes
HOW? Class IIa in suspected hypomagnesemia, TdP,
and Class IIb in VF/VT: 1 - 2gm slow IVP in 100ml
WHAT?
Hypotension at large doses
Drugs Used for Heart Rhythm
and Rate
Procainamide
WHY?
Suppresses both ventricular and atrial
arrhythmias
Type Ia antiarrhythmic, affects fast Na+channelsslowing conduction velocity, prolongs RP, and
decreases automaticity
Phase IV depolarization
WHEN?
Refractory/recurrent VF/VT
Control of rapid ventricular response (IIb)
Conversion SVT (AF/Fl) (IIa)
Drugs Used for Heart Rhythm
and Rate
Procainamide
HOW? VF: 20-30 mg/min slow infusion (max=17
AF with rapid vent. response: 100 mg over 5
then infuse@ 1 - 4 mg/min
1-2 gm/250ml D5W
mg/kg)
min
WHAT?
Stop infusion if patient hypotensive, widened QRS
>50%,
arrhythmia suppression, or dose=17mg/kg
Dose reduction in renal failure
SLE syndrome
Levels:
PA=4-12 g/ml
NAPA=7-15 g/ml (active metabolite-Class III)
Drugs Used for Heart Rhythm
and Rate
Lidocaine
WHY?
Type IB antiarrhythmic
Affects fast Na+ channels, shortens refractory period
Suppresses spontaneous depolarization
Local anesthetic, increases fibrillation threshold
Suppresses ventricular ectopy post-MI
Without effecting myocardial contractility, BP or AV nodal conduction
WHEN?
SECOND-CHOICE agent
VT/VF refractory to electrical countershock and epinephrine
(Indeterminate)
Control of PVCs (Indeterminate)
Hemodynamically stable VT (IIb)
Not for routine prophylaxis post-MI, however, accepted in high-risk
patients
(hypokalemia, myocardial ishchemia, LV dysfunction)
Drugs Used for Heart Rhythm
and Rate
Lidocaine
HOW? Class IIa: 1 - 1.5 mg/kg IVP q5 - 10 min (max=3mg/kg)
Infusion (with pulse): 1 - 4 mg/min (if pulse is regained)
Therapeutic Levels: 1.5-6 g/ml
ET Dose: 2-2.5 times IV dose
Preparation: 1-2 gm/250 ml D5W or NS
WHAT?
Hepatic metabolism, renal elimination
Bradycardia, cardiac arrest, seizures
Lidocaine toxicity/neurotoxicity - twitching, LOC,
seizures, coma
Lidocaine levels persist in low CO states
Drugs Used to Improve Cardiac Output and
Blood Pressure
Sodium Bicarbonate
WHY? Enhances sodium shift intracellularly, buffers
acidosis,
decreases toxicity of TCAs, increases clearance of acidic drugs
WHEN?
Class I - hyperkalemia
Class IIa - bicarbonate-responsive acidosis metabolic
acidosis secondary to loss of bicarb (renal/GI);
overdoses (TCAs, phenobarbital, aspirin)
Class IIb - protracted arrest in intubated patients
Class III - hypoxic lactic acidosis
HOW? 1 mEq/kg IVP, 0.5mEq/kg q10 min prn
WHAT? May worsen outcome if not intubated/ventilated.
Metabolic alkalosis, decreased O2 delivery to tissues, hypokalemia,
CNS acidosis, hypernatremia, hyperosmolarity
Incompatible with calcium, epinephrine, atropine, norepinephrine, isoproterenol
Summary
[Link] and Pulseless [Link]
Changes:
Vasopressin added - Class IIb 40 U IVP x 1
Epinephrine - Class Indeterminate 1mg IVP q 3-5
min
Amiodarone added - Class IIb
300mg IVP (cardiac arrest dose). May repeat 150mg x 1
Lidocaine - Class Indeterminate 1-1.5 mg/kg IVP q 35 min (Max = 3mg/kg)
Procainamide is acceptable but not recommended
due to long administration times
Bretylium fell off algorithm due manufacturing
problems
The Tachycardia
Algorithms
Major New Concepts:
Make a specific rhythm diagnosis
Identify patients with significantly
impaired cardiac function (EF<40%,
overt HF)
Only use one antiarrhythmic, especially
in damaged hearts
Resulted in 3 new algorithms
The Tachycardia Overview Algorithm
Is the patient stable or unstable?
Stable
Unstable
Identify 1 of 4 types of tachycardia
Cardioversion
(premedicate)
AF/Aflutter
Narrow-complex VT, PSVT,
tachycardia
Stable wide-complex
tachycardia
Stable monomorphic VT
100J, 200J,
360J
300J,
Tachycardia - Atrial
Fibrillation/Flutter
4 Clinical Features:
Unstable?
Impaired cardiac function?
WPW?
Duration? <48h, or > 48h?
Focus - treat unstable patients urgently
Control ventricular response convert
anticoagulate
Condition
Atrial
Fibrillation/Flutter
Rate Control
EF > 40%
CCB (I)
-Blocker (I)
EF < 40%
Digoxin (IIb)
Diltiazem (IIb)
Amiodarone (IIb)
WPW
Preserved heart
fxn:
DC Cardioversion
Amiodarone(IIb)
Flecainide (IIb)
Procainamide (IIb)
Propafenone (IIb)
Sotalol (IIb)
Impaired
EF<40%:
DC Cardioversion
Amiodarone(IIb)
Conversion
> 48h
DC Cardioversion
Amiodarone (IIa)
Ibutilide (IIa)
Flecainide (IIa)
Propafenone (IIa)
Procainamide (IIa)
DC Cardioversion
OR
Amiodarone (IIb)
Conversion
< 48h
No DC Cardioversion
Anticoagulation x 3
weeks, then CV, then
anticoagulation x 4 wk
OR r/o clot by TEE,
CV, then AC x 4 wk
(See above)
DC Cardioversion
Amiodarone (IIb)
Flecainide (IIb)
Propafenone (IIb)
Procainamide (IIb)
Sotalol (IIb)
(See above)
Drugs Used in Afib/AFlutter
Calcium channel blockers
Beta-blockers
Digoxin
Amiodarone
Procainamide
Flecainide (IV form in ACLS -not available in US)
Propafenone (IV form in ACLS -not available in
US)
Sotalol (IV form in ACLS -not available in US)
Drugs Used for Heart Rhythm
and Rate
Calcium Channel Blockers
WHY? Blocks inward flow of Ca and Na, slows conduction, RP in
AVN
Terminate reentrant arrhythmias requiring AVN
conduction
Control ventricular response rate in AF/AFl
Coronary vasodilation
May exacerbate CHF
Verapamil: Negative inotrope & chronotrope (good anti-ischemic)
Class I for acute and preventative SVT
Diltiazem: Direct negative chronotropic effect, mild negative
inotrope
Highly effective in controlling ventricular response in A Fib
WHEN?
Control ventricular response rate in patients with
AF/Fl, or MAT
Verapamil: PSVT not requiring cardioversion
Drugs Used for Heart Rhythm
and Rate
Calcium Channel Blockers
HOW? Verapamil: 2.5 - 5 mg IVP, over 2 min (max=30mg)
Inf @ 5-10 mg/hr
Diltiazem: 0.25 mg/kg IVP, may repeat with
0.35mg/kg in 15 min
Infuse @ 5-15 mg/hr
WHAT?
Contraindicated in wide QRS complex
tachycardias and
ventricular tachycardias,
exacerbation of CHF in patients
with LV dysfunction
Transient decrease in BP
Avoid in sick sinus syndrome of AV block (w/out pacer)
May potentiate digoxin toxicity.
Incompatible with bicarbonate, epinephrine, furosemide
Drugs Used for Heart Rhythm
and Rate
Beta - Blockers
WHY? B-adrenergic blockade, slows conduction and
increases refractory period in AV node
WHEN?
reduces
post-
AMI (reduces rate of reinfarction),
recurrent ischemia and incidence of VF in
MI patients, USA
HOW? Atenolol:
2.5-5 mg IV over 5 min
Metoprolol:
5 - 10 mg IVP q 5 min
Propranolol:
0.1 mg/kg IV divided into 3
doses @ 2 - 3 min intervals
Esmolol: 500 mcg/kg over 1 min
Inf @ 50 mcg/kg/min
WHAT?
heart
Hypotension, bradycardia, AV block, overt
failure or severe bronchospasm/COPD
Stable Monomorphic Ventricular Tachycardia
Preserved
Cardiac
Function
NOTE!
May go directly to
cardioversion
Medications: any one
Procainamide (IIA)
Sotalol (IIA)*
Amiodarone (IIB)
Lidocaine (IIB)
*Not yet available in the US.
Impaired LV
EF<40% or
CHF
Amiodarone (IIB)
150 mg IV bolus over 10 min
may repeat 150mg q10-15min or
start infusion
OR
Lidocaine (IIB)
0.5 to 0.75 mg/kg IV push
Then use
Synchronized cardioversion
Narrow-Complex Supraventricular
Tachycardia
Vagal stimulation
Adenosine
Junctional
1. EF > 40% - Amiodarone, B-blocker, CCB
2. EF <40%, CHF - Amiodarone
PSVT
EF>40% - CCB, BB, digoxin, DC cardioversion
(procainamide, amiodarone, sotalol)
EF<40%, CHF - no DC cardioversion; digoxin,
amiodarone, diltiazem
MAT
EF>40% -No DC cardioversion; CCB, BB, amiodarone
EF<40% -No DC cardioversion; amiodaonre, diltiazem
Wide-Complex Tachycardia
Wide . Prolonged QRS or QRST interval
HR > 120 bpm (ex. VT, sinus tachycardia, [Link])
OLD - Lidocaine
NEW Establish diagnosis - 12-lead ECG
Adenosine if SVT- slows AV conduction. Short-lived
hypotension
Amiodarone (IIa) normal LV function
Amiodarone (IIb) impaired LV function
Procainamide (IIa)- terminates SVT due to altering
conduction across accessory pathways
Lidocaine if VT
Sotalol, propafenone, flecainide
Drugs Used for Heart Rhythm
and Rate
Adenosine
WHY? Endogenous nucleoside, slows conduction through the
node and can interrupt AV nodal reentry pathways
WHEN?
PSVT (half-life=10 sec)
If PSVT persists may want longer acting agent
diltiazem)
AV
(verapamil or
HOW? 6 mg rapid IV over 1 - 3 sec, followed by 20 ml
May repeat in 1-2min with 12 mg dose.
Max.=30 mg
NS flush.
WHAT?
Flushing, dyspnea, chest pain, post-conversion
bradycardia
Drug interaction with theophylline, dipyridamole
Pulseless Electrical Activity
PEA no pulse with + electrical activity (not VF/VT)
Reversible if underlying cause is reversed (5 Hs, 5
Ts)
Hypovolemia, hypoxia, hydrogen ion (acidosis),
hyper/hypokalemia, hyper/hypothermia
Tablets, tamponade, tension pneumothorax, thrombosis (ACS),
thrombosis (PE)
Intervention Comments/Dose
Problem
(HCO3)
Search for the probable cause and intervene
Epinephrine 1 mg IV q3-5 min.
Atropine
With slow heart rate, 1 mg IV q3-5 min.
dose 0.04 mg/kg)
(max.
Atropine
WHY? Anticholinergic/direct vagolytic
Enhances sinus node automaticity and AVN conduction
WHEN?
PEA, symptomatic sinus bradycardia, asystole,
HOW? Bradycardia: 0.5 -1 mg IV q3-5 min
Asystole: 1 mg IV q 3-5 min
Max = 0.04 mg/kg or 3 mg
ET Dose=1-2mg diluted in 10ml
Paradoxical bradycardia with
insufficient dose (<0.5mg)
WHAT?
Tachycardia; 2nd or 3rd degree AV block
(paradoxical
slowing may occur), MI (may worsen
ischemia/HR)
Incompatible with bicarbonate, epinephrine & norepinephrine
Bradycardia
All Patients Deserve Empathy
(The sequence reflects interventions for increasingly severe bradycardia)
Absolute (< 60 BPM) or relative
Serious signs and symptoms (CP, SOB, hypotension, mental
status changes)
Mnemonic
Intervention
All
mg/kg)
Atropine
Comments/Dose
0.5-1.0 mg IVP q 3-5 min (max 0.03-0.04
Patients
Pacing
severe S/S
Deserve
Dopamine
Empathy
Epinephrine
Use Transcutaneous Pacing if
5-20 g/kg/min.
2-10 g/min.
Medications for Bradycardia
Atropine - Why? How?
Dopamine
Epinephrine infusion
1mg/250 ml @ 1-4 mcg/min
Note: Lidocaine can be lethal if HR is due to
ventricular escape rhythm
Dopamine
WHY? NE precursor
Stimulates DA, & -adrenergic receptors (dose-related)
Want -stimulation, for bradycardia-induced
hypotension
WHEN?
Hypotension/shock
HOW? renal: 2 - 5 mcg/kg/min
cardiac:
5 - 10 mcg/kg/min (B1 & alpha)
vascular: 10 - 20 mcg/kg/min ( alpha)
Preparation:
400 mg/250 ml D5W or NS
WHAT?
Tachycardia, tachyphylaxis, proarrhythmic
If requiring > 20mcg/kg/min consider adding NE
ACLS Algorithms
Asystole
Consider possible causes and treat accordingly
([Link], hyper/hypokalemia, acidosis)
Acronym TEA
T Transcutaneous Pacing (TCP) (Class IIb) Only
effective with early implementation along with
appropriate interventions and medications
E
Epinephrine 1 mg IV q3-5 min.
Atropine 1 mg IV q3-5 min. (max. dose 0.04 mg/kg)
Discourage shocking due to excess parasympathetic
discharge
Consider Na Bicarbonate 1 mEq/kg
Drugs Used for
Myocardial Ischemia/Pain
Oxygen
Nitroglycerin
Morphine Sulfate
AMI - Aspirin, thrombolytics, heparin,
lidocaine, beta-blockers
Glycoprotein IIb/IIIa receptor antagonists
Acute Myocardial Infarction
Call first, call fast, call 911
Oxygen 4L/min
NTG SL, paste or spray; if BP > 90 mm Hg, IV
NTG
Morphine IV
ASA PO (I)
Thrombolytics? (I) - within 6 hours of
symptoms, (II) if > 6hr
IV heparin
B-blockers
Magnesium (if Mg)
Oxygen
Why?
increases hemoglobin saturation,
improves tissue oxygenation
supply to ischemic tissues
16-17% oxygen from mouth-to-mouth
When?
Must give supplemental oxygen in ACLS
Always for MI
How?
NC 4 L/min, intubation, etc
Goal - Osat=97-98%
Confirm tube placement
Drugs Used for Myocardial
Ischemia/Pain
WHY?
Nitroglycerin
binds to receptors on vascular smooth muscle vasodilation (venous > arterial)
venous BF to heart (preload) & O2
consumption
dilates coronary arteries - myocardial blood
supply
antagonizes vasospasm
increases collateral flow to ischemic
myocardium
inhibits infarct expansion
decreases pain
Drugs Used for Myocardial
Ischemia/Pain
Nitroglycerin
WHEN?
Ischemic CP; USA; pulmonary edema (when SBP>100); AMI
SL NTG -drug of choice for angina
IV NTG - drug of choice for unstable angina or AMI
Congestive heart failure with ischemia
HOW?
IV: 10-20 mcg/min, increase by 5-10 mcg/min q5-10 min until desired
effect or hemodynamic compromise
SL: 1 tablet (0.4mg) SL q5min times 3
Spray: 1 spray onto oral mucosa
Ointment 2%: 1-2 inches over 2-4 inch area
Patches: no role in acute therapy
Drugs Used for Myocardial
Ischemia/Pain
Nitroglycerin
Preparation: 50 mg/250 ml D5W or NS
Must be in glass bottle
Cautions:
hypotension - treat with fluids, and rate
reduction/elimination
bradycardia - vasovagal reflex to hypotension
treat with fluids, rate reduction, atropine
reflex tachycardia also a concern
headache, dizziness - may be diminished by laying
down
patients develop tachyphylaxis to effects - promote
nitrate-free periods, intermittent dosing and
lowest-possible doses
Drugs Used for Myocardial
Ischemia/Pain
Morphine Sulfate
WHY? (Pain can catecholamines - BP, HR, O2 demands)
Opiate analgesic
pain, preload and afterload, SVR, anxiety
Relieves pulmonary congestion, myocardial oxygen demand
WHEN?
Pain, pulmonary edema, BP > 90 mm Hg
HOW?
1-3mg IVP (2-15 mg IVP q15-30 min prn)
CAUTION?
Respiratory & CNS depression, bradycardia, hypotension, N/V
Drugs Used for Myocardial
Ischemia/Pain
(Continued)
Aspirin
Heparin
Thrombolytics - reteplase,
alteplase, TNK
B Blockers
Magnesium
Lidocaine - not for prophylaxis
Hypotension/Shock/Pulmona
ry Edema
Identify Problem? Volume; Pump; Rate?
Volume:
fluids, blood, vasopressors
Pump:
s/s of shock - vasopressors; no s/s shock dobutamine
BP (>100 mm Hg) - NTG, Nitroprusside
pulmonary edema -furosemide 0.51mg/kg, morphine 1-3mg, NTG SL,
oxygen/intubate
Rate: see algorithms
Drugs Used to Improve Cardiac
Output and Blood Pressure
Norepinephrine
Action:
Alpha & -adrenergic
stimulation, increases
contractility
and HR, vasoconstriction, improves
coronary blood flow
Indication:
severe
Shock refractory to fluid replacement,
hypotension
Dose:
0.5 - 1 mcg/min
refractory shock = 8 - 30 mcg/min
Preparation:
4-8mg/250 ml D5W or NS
Caution:
Hypertension, myocardial ischemia,
cardiac arrest,
palpitations
Drugs Used to Improve Cardiac
Output and Blood Pressure
Dobutamine
Action:
B1- adrenergic activity
Indication:
Inotrope in heart failure/hypotension
Dose:
2 - 20 mcg/kg/min
Preparation:
250 mg/250 ml D5W or NS
Caution:
tachyarrhythmias,worsens myocardial
ischemia
Drugs Used to Improve Cardiac
Output and Blood Pressure
Inamrinone and Milrinone
Action:
Phosphodiesterase inhibitors, positive
inotropes and
vasodilator
Indication:
Refractory heart failure
Dose: Inamrinone: 750 mcg/kg over 2 - 3 min
Inf @ 5 - 15 mcg/kg/min
Milrinone: 50 mcg/kg over 10 min
Inf @ 0.375 - 0.75 mcg/kg/min
Caution:
Thrombocytopenia, worsens myocardial
ischemia, SV and ventricular arrhythmias
Drugs Used for Heart Rhythm
and Rate
Isoproterenol
WHY? Synthetic sympathomimetic amine
Pure B-adrenergic activity +inotropic& chronotrope
HR/CO, contractility; MAP secondary vasodilation
WHEN? Symptomatic bradycardia
Refractory torsades de pointes
HOW?
Class II - 2 - 10 mcg/min
Class III - higher doses
Preparation: 1 mg/ 250 ml D5W or NS
WHAT?
mycocardial O2 consumption & peripheral vasodilation
Avoid in ischemic heart disease; arrhythmogenic
Drugs Used to Improve Cardiac
Output and Blood Pressure
Sodium Nitroprusside
Action:
Antihypertensive, peripheral vasodilator,
reduces afterload, increases CO and relieves
pulmonary
congestion
Indication:
Hypertension, AMI, CHF
Dose: 0.1 - 5 mcg/kg/min, and titrate up to 10mcg/kg/min
Preparation: 50 mg/250 ml D5W
Caution:
Cyanide and thiocyanate toxicity,
hypotension
Summary of 2000
Changes
NEW AGENTS - Amiodarone & Vasopressin
Amiodarone (Class IIb) & Procainamide (Class IIb) hemodynamically stable wide-complex tachycardia (esp. in
poor cardiac fxn)
VT - amiodarone & sotalol (Class IIa)
Vasopressin (Class IIb) - alternative to epinephrine
Bretylium acceptable, but not recommended
Lidocaine for VT/VF (Class Indeterminate) & Class III for
prophylaxis of ventricular arrhythmias in AMI
Magnesium (Class IIb) - Mg or TdP
High-dose epinephrine (Class Indeterminate)
Fibrinolytics for AMI & Stroke
Crash Cart Revisions
Summary of Changes:
Additions: 5 amps of amiodarone 150mg/3ml (were
3)
3 vials of vasopressin (20 Units/vial)
1 bag of premixed dopamine 400mg in 250ml
4 Na Bicarbonate syringes (were 3)
5 filter needles
20 blunt cannulas
Deletions:
Remove
Remove
Remove
1 dopamine vial (new total=1)
5 epinephrine syringes (new total=10)
1 lidocaine syringe (new total=2)
metoprolol
Needless System/Cannulas
Questions ?